A New Culprit in Atherosclerosis?

Published Online: Saturday, March 1, 2003

Researchers from Wake Forest University and the University of California, San Francisco, have found that an enzyme known as acyl CoA:cholesterol acyltransferase 2 (ACAT2) affects the way cholesterol is circulated and stored in the body, possibly leading to accumulation in the arteries, which can lead to atherosclerosis. This enzyme is found in the liver and the intestines. By removing ACAT2 in mice, Lawrence L. Rudel, PhD, and his team found that hardening of arteries was virtually prevented.

Experts are now looking to develop a drug that inhibits ACAT2. Previous attempts at developing a similar drug were unsuccessful because researchers did not realize that there were 2 forms of the enzyme, ACAT1 and ACAT2.

According to Prediman K. Shah, MD, director of the Atherosclerosis Research Center at Cedars-Sinai Medical Center in Los Angeles, Calif, a new drug would have to specifically block ACAT2. Further research is needed to determine the side effects of inhibiting this enzyme.

Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues